Cell Impact's rights issue is oversubscribed
Cell Impact AB (publ) (Nasdaq First North Growth Market: CI B) ("Cell Impact" or the "Company") announces that the preliminary outcome for the rights issue (the "Rights Issue"), for which the subscription period ended on December 23, 2021, indicates that the Rights Issue is oversubscribed and that no guarantee commitments will need to be utilized. The Rights Issue will provide the Company with approximately SEK 349 million before deduction of transaction costs related to the Rights Issue.
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN CELL IMPACT AB (PUBL). SEE ALSO THE SECTION "IMPORTANT INFORMATION" BELOW IN THIS DOCUMENT.
The Board of Directors in Cell Impact resolved on November 29, 2021 pursuant to the authorization granted by the extra general meeting on November 16, 2021, on a fully guaranteed Rights Issue of up to approximately SEK 349 million.
The preliminary outcome indicates that approximately 15.8 million series B shares, corresponding to approximately 94 percent of the offered series B shares, have been subscribed for with subscription rights in the Rights Issue. Additionally, applications for subscription of approximately 12.0 million series B shares without subscription rights, corresponding to approximately 71 percent of the offered series B shares, have been received. Thus, the preliminary outcome indicates that the Rights Issue is oversubscribed and that no guarantee commitments will be utilized.
Notice of allotment
Those who have subscribed for series B shares without subscription rights will be allocated series B shares in accordance with the principles set out in the prospectus published on December 6, 2021. Notice of allotment to the persons who subscribed for series B shares without subscription rights is expected to be distributed on December 28, 2021. Subscribed and allotted series B shares shall be paid in cash within two banking days in accordance with the instructions on the settlement note sent to the subscriber. Subscribers who have subscribed through a nominee will receive notification of allocation in accordance with their respective nominee's procedures. Only those who have been allotted shares will be notified.
The final outcome of the Rights Issue is expected to be published around December 27, 2021. The last day of trading in paid subscribed shares (BTAs) is expected to be on January 4, 2022. The new series B shares subscribed for with and without subscription rights are expected to be traded on Nasdaq First North Growth Market as from January 11, 2022.
In conjunction with the Rights Issue, the Company has engaged Carnegie Investment Bank AB (publ) as Sole Global Coordinator and Joint Bookrunner and Bryan, Garnier & Co as Joint Bookrunner. Advokatfirman Vinge and Advokatfirman Wåhlin AB act as legal advisers.
This information is information that Cell Impact AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation.
For more information, please contact:
Pär Teike, CEO, +46 73-024 06 84 or [email protected].
About Cell Impact
Cell Impact AB (publ) is a global supplier of advanced flow plates to fuel cell manufacturers. The company has developed and patented a unique method for high-velocity forming, Cell Impact Forming™, which makes it possible to produce flow plates with more advanced designs, which in turn creates more cost and energy-efficient fuel cells compared to conventional forming methods.
The Cell Impact share is listed on Nasdaq First North Growth Market and FNCA Sweden AB is the company's Certified Advisor (CA). Contact info: +46 8-528 00 399 or [email protected].
Publication, release, or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where the press release has been made public or distributed should be informed of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer or solicitation to buy or subscribe for any securities in Cell Impact AB (publ) in any jurisdiction, either from Cell Impact AB (publ) or from anyone else.
This press release is not a prospectus according to the definition in Regulation (EU) 2017/2019 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. A prospectus will be prepared by the Company and published on the Company's website after the prospectus has been reviewed and approved by the Swedish Financial Supervisory Authority.
This press release does not constitute an offer or solicitation to buy or subscribe for securities in the United States. The securities mentioned herein may not be sold in the United States without registration, or without an exemption from registration, under the U.S. Securities Act from 1933 ("Securities Act"), and may not be offered or sold within the United States without being registered, covered by an exemption from, or part of a transaction that is not subject to the registration requirements according to the Securities Act. There is no intention to register any securities mentioned herein in the United States or to issue a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, wholly or in part, in or to Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa, the United States or any other jurisdiction where the release, publication or distribution of this information would violate current rules or where such an action is subject to legal restrictions or would require additional registration or other measures beyond those that follow from Swedish law. Actions in contravention of this instruction may constitute a violation of applicable securities legislation.
This press release contains forward-looking statements related to the Company's intentions, estimates or expectations with regard to the Company's future results, financial position, liquidity, development, outlook, estimated growth, strategies and opportunities as well as the markets in which the Company is active. Forward-looking statements are statements that do not refer to historical facts and can be identified by the use of terms such as "believes", "expects", "anticipates", "intends", "estimates", "will", "may", "implies", "should", "could" and, in each case, their negative, or comparable terminology. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there is no guarantee that they will occur or that they are correct. Since these assumptions are based on assumptions or estimates and involve risks and uncertainties, actual results or outcomes, for many different reasons, may differ materially from those what is stated in the forward-looking statements. Due to such risks, uncertainties, eventualities and other significant factors, actual events may differ materially from the expectations that expressly or implicitly are contained in this press release through the forward-looking statements. The Company does not guarantee that the assumptions which serve as a basis for the forward-looking statements in this press release are correct, and each reader of the press release should not rely on the forward-looking statements in this press release. The information, opinions and forward-looking statements that expressly or implicitly are stated herein are provided only as of the date of this press release and may change. Neither the Company nor any other party will review, update, confirm or publicly announce any revision of any forward-looking statement to reflect events that occur or circumstances that arise with respect to the contents of this press release, beyond what is required by law or Nasdaq First North Growth Market Rulebook.
Potential investors should not put undue trust in the forward-looking statements herein, and potential investors are strongly recommended to read the sections in the prospectus that include a more detailed description of the factors that can affect the Company's business and its associated market.
Cell Impact AB (Nasdaq First North GM: CI) kommer att installera en Cell Impact Forming™ demonstrationslinje för flödesplattor i Japan i samarbete med F.C.C. Co., Ltd., en ledande japanska leverantör av komponenter till fordonsindustrin.
Cell Impact AB (Nasdaq First North GM: CI) will set up a Cell Impact Forming™ flow plate demonstration line in Japan in collaboration with leading Japanese auto parts supplier F.C.C. Co., Ltd.
Cell Impact AB (Nasdaq First North GM: CI) lämnar följande finansiella sammanfattning för andra kvartalet.
Cell Impact AB (Nasdaq First North GM: CI) reports the following financial summary for the second quarter.
Cell Impact AB:s (Nasdaq First North GM: CI) helägda dotterbolag Cell Impact Japan Inc. har fått en order värd 1.6 MSEK. Ordern omfattar ett projekt för designutveckling av en flödesplatta och inkluderar produktion av prototypplattor. Det är en fortsättning på tidigare etablerade aktiviteter i Japan och leverans kommer att ske under tredje kvartalet 2022.
Cell Impact AB's (Nasdaq First North GM: CI) wholly owned subsidiary Cell Impact Japan Inc. has received an order worth MSEK 1.6. The order is for a flow plate design project and involves flow plate prototype production. It is a continuation of earlier established activities in Japan and will be delivered during the third quarter of 2022.
Årsstämman i Cell Impact AB (publ) ("Cell Impact" eller "Bolaget") den 21 april 2022 beslutade i enlighet med styrelsens förslag om ändring av Cell Impacts bolagsordning innebärande borttagande av aktieslaget A-aktier. Bolagets B-aktier kommer därmed vara ordinarie aktier. Aktiens röstvärde har även ändrats från 1/10 röst per aktie till 1 röst per aktie.
The Annual General Meeting of Cell Impact AB (publ) ("Cell Impact" or the "Company") on April 21, 2022 resolved, in accordance with the boards of director's proposal, on amendments of Cell Impact's articles of association including the removal of the class A share. The Company's class B shares will therefore be ordinary shares. The share's voting value has also been changed from 1/10 vote per share to 1 vote per share.
Cell Impact AB (Nasdaq First North GM: CI B) lämnar följande finansiella sammanfattning för första kvartalet.
Cell Impact AB (Nasdaq First North GM: CI B) reports the following financial summary for the first quarter.
Cell Impact AB (Nasdaq First North GM: CI B) meddelar att IF Metalls verkstadsklubb på Cell Impact har utsett Lillette Hallblad som arbetstagarrepresentant i Cell Impacts styrelse.
Cell Impact AB (Nasdaq First North GM: CI B) announces that the local IF Metall union club at Cell Impact has elected Lillette Hallblad as employee representative to Cell Impact's Board of Directors.
Årsstämma i Cell Impact AB (Nasdaq First North GM: CI B) hölls den 21 april 2022.
The annual general meeting of Cell Impact AB (Nasdaq First North GM: CI B) was held on April 21, 2022.
Aktieägarna i Cell Impact AB (publ) (Nasdaq First North GM: CI B), org.nr 556576-6655, kallas härmed till årsstämma torsdagen den 21 april 2022 klockan 14.00 i IVA Konferenscenter, Grev Turegatan 16, Stockholm. Inregistrering sker från kl. 13.15.
The shareholders of Cell Impact AB (publ) (Nasdaq First North GM: CI B), reg. no. 556576-6655, are hereby invited to participate in the annual general meeting to be held on Thursday 21 April 2022, 14.00 hours (CET), at the premises of the Royal Swedish Academy of Engineering Sciences (IVA Konferenscenter), Grev Turegatan 16, Stockholm, Sweden. Registration from 13:15 hours (CET).
Cell Impact AB (Nasdaq First North GM: CI B) lämnar följande finansiella sammanfattning för fjärde kvartalet.
Cell Impact AB (Nasdaq First North GM: CI B) reports the following financial summary for the fourth quarter.
Cell Impact AB